INVITATION

DATE 19 May 2023 TIME 13:15 -14:45 LOCATION Liffey Hall 1

European Congress on Obesity Rhythm Satellite Symposium ECO 2023

Hyperphagia and early-onset, severe obesity:

What does good multidisciplinary team (MDT) care look like for patients living with MC4R pathway diseases?

We look forward to welcoming you to this dynamic, discussion-based session.

For more details and to stay updated with the latest symposium information, visit **www.Path4HCPs.com**

📺 ТОРІС	
Welcome and introductions	All Moderated by: Prof. Carel Le Roux
Understanding hyperphagia – what does it mean to be genetically hungry?	Prof. Carel Le Roux
The MC4R pathway – genetic impairments: a root cause of hyperphagia and early-onset, severe obesity	Prof. Sadaf Farooqi
Bardet-Biedl Syndrome – the real-life burden of hyperphagia on patients and caregivers	Dr. Elizabeth Forsythe
The importance of early diagnosis and genetic testing	All Moderated by: Prof. Carel Le Roux
What does good MDT care look like for patients living with MC4R pathway diseases?	All Moderated by: Prof. Carel Le Roux
Q&A	All Moderated by: Prof. Carel Le Roux
Summary and close	Prof. Carel Le Roux

This discussion is intended for HCPs only and a Rhythm Pharmaceuticals medicinal product may be discussed at the symposium.

Adverse events should be reported. Reporting forms and information in ROI can be found at www.hpra.ie, and in the UK at https://yellowcard.mhra.gov.uk. Adverse events should also be reported to Rhythm Pharmaceuticals on medinfo@rhythmtx.com. Copies of the Summary of Product Characteristics or Prescribing Information for the UK and Ireland are https://www.hpra.ie, and in the UK at https://www.hpra.ie, and in the medinfo@rhythmtx.com. Copies of the Summary of Product Characteristics or Prescribing Information for the UK and Ireland are https://www.hpra.ie, and in the summary of Product Characteristics or Prescribing Information for the UK and Ireland are https://www.hpra.ie, and https://www.hpra.ie, and in the www.hpra.ie, and in the mailto:summary of Product Characteristics or Prescribing Information for the UK and Ireland are https://summary of Product Characteristics or mailto:summary of Product Characteristics or mailto:summary of Product Characteristics or www.hpra.ie, and in the www.hpra.ie, and in the https://www.hpra.ie, and in the www.hpra.ie, and in the mailto:summary of Product Characteristics or mailto:summary of Product Characteristics or mailto

© 2023. Rhythm Pharmaceuticals, Inc. All rights reserved. Rhythm and its logo are trademarks of Rhythm Pharmaceuticals, Inc. This meeting is organised and funded by Rhythm Pharmaceuticals. AT-DSE-2300073 05/2023

